» Articles » PMID: 18461284

Rho GTPases in PC-3 Prostate Cancer Cell Morphology, Invasion and Tumor Cell Diapedesis

Overview
Specialty Oncology
Date 2008 May 8
PMID 18461284
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The Rho GTPases comprise one of the eight subfamilies of the Ras superfamily of monomeric GTP-binding proteins and are involved in cytoskeletal organization. Previously, using a dominant negative construct, we demonstrated a role for RhoC GTPase in conferring invasive capabilities to PC-3 human prostate cancer cells. Further, we demonstrated that inactivation of RhoC led to morphological changes commensurate with epithelial to mesenchymal transition (EMT) and was accompanied by increased random, linear motility and decreased directed migration and invasion. EMT was related positively to sustained expression and activity of Rac GTPase. In the current study we analyze the individual roles of RhoA, RhoC and Rac1 GTPases in PC-3 cell directed migration, invasion and tumor cell diapedesis across a human bone marrow endothelial cell layer in vitro.

Results: Use of specific shRNA directed against RhoA, RhoC or Rac1 GTPases demonstrated a role for each protein in maintaining cell morphology. Furthermore, we demonstrate that RhoC expression and activation is required for directed migration and invasion, while Rac1 expression and activation is required for tumor cell diapedesis. Inhibition of RhoA expression produced a slight increase in invasion and tumor cell diapedesis.

Conclusions: Individual Rho GTPases are required for critical aspects of migration, invasion and tumor cell diapedesis. These data suggest that coordinated activation of individual Rho proteins is required for cells to successfully complete the extravasation process; a key step in distant metastasis.

Citing Articles

Proteomic Analysis of Prostate Cancer FFPE Samples Reveals Markers of Disease Progression and Aggressiveness.

Lygirou V, Fasoulakis K, Stroggilos R, Makridakis M, Latosinska A, Frantzi M Cancers (Basel). 2022; 14(15).

PMID: 35954429 PMC: 9367334. DOI: 10.3390/cancers14153765.


Role of RhoC in cancer cell migration.

Lou Y, Jiang Y, Liang Z, Liu B, Li T, Zhang D Cancer Cell Int. 2021; 21(1):527.

PMID: 34627249 PMC: 8502390. DOI: 10.1186/s12935-021-02234-x.


The Effect of Ras Homolog C/Rho-Associated Coiled-Protein Kinase (Rho/ROCK) Signaling Pathways on Proliferation and Apoptosis of Human Myeloma Cells.

Feng X, Zhang L, Nie S, Zhuang L, Wang W, Huang J Med Sci Monit. 2019; 25:7605-7616.

PMID: 31599230 PMC: 6798802. DOI: 10.12659/MSM.915998.


MicroRNA-138 Inhibits Osteogenic Differentiation and Mineralization of Human Dedifferentiated Chondrocytes by Regulating RhoC and the Actin Cytoskeleton.

Zheng H, Ramnaraign D, Anderson B, Tycksen E, Nunley R, McAlinden A JBMR Plus. 2019; 3(2):e10071.

PMID: 30828688 PMC: 6383697. DOI: 10.1002/jbm4.10071.


Role of the lncRNA ABHD11-AS in the tumorigenesis and progression of epithelial ovarian cancer through targeted regulation of RhoC.

Wu D, Chen X, Sun K, Wang L, Chen S, Zhao Y Mol Cancer. 2017; 16(1):138.

PMID: 28818073 PMC: 5561620. DOI: 10.1186/s12943-017-0709-5.


References
1.
Kamai T, Tsujii T, Arai K, Takagi K, Asami H, Ito Y . Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res. 2003; 9(7):2632-41. View

2.
van Golen K, Wu Z, Qiao X, Bao L, Merajver S . RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000; 60(20):5832-8. View

3.
Aktories K, Hall A . Botulinum ADP-ribosyltransferase C3: a new tool to study low molecular weight GTP-binding proteins. Trends Pharmacol Sci. 1989; 10(10):415-8. DOI: 10.1016/0165-6147(89)90191-0. View

4.
Cooper C, Pienta K . Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview. Prostate Cancer Prostatic Dis. 2002; 3(1):6-12. DOI: 10.1038/sj.pcan.4500387. View

5.
Aukerman S, Price J, Fidler I . Different deficiencies in the prevention of tumorigenic-low-metastatic murine K-1735b melanoma cells from producing metastases. J Natl Cancer Inst. 1986; 77(4):915-24. View